Stereotaxis, Inc. (STXS)
Healthcare · ASE
Price as at 1 Oct 2026, 02:02 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Stereotaxis, Inc. trades at $1.23, which is 51% above the $0.60 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 32 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
STXS earnings and analyst estimates
Recommendation mix, 4 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Stereotaxis, Inc.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a Synchrony and SynX Solution offer integrated, real-time information solution to manage, control, record and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including MAGiC catheter, a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures; MAGiC Sweep, a mapping catheter; QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; and V-CAS devices. Further, it provides interventional devices under the Map-iT, MAGiC, and EMAGIN brands, and other related devices. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
STXS passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
3 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$338.2K · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$314.9K · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$26.5K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
STXS peers
The largest companies in the same industry (Medical Instruments & Supplies), then in the same sector.
- MDLN Medline Inc.
- RSMDF ResMed Inc.
- SRT3.DE Sartorius Aktiengesellschaft
- SOLV Solventum Corporation
- BAX Baxter International Inc.
- RGEN Repligen Corporation
- AVTR Avantor, Inc.
- TFX Teleflex Incorporated
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Stereotaxis, Inc. (STXS) undervalued?
Against our fair value estimate of $0.60, STXS at $1.23 is 51% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own STXS?
3 of the institutions we track reported a position in STXS in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its STXS data?
Fundamentals for STXS come from company filings and exchange data, as listed on ASE; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 02:02 UTC and is delayed. Our data quality score for this company is 83/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for STXS, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.